BRAF and metastasis: We also performed univariate analysis to evaluate the predictive value of clinicopathologic factors for DCR, including age (≥ 60 vs. < 60), ECOG (1 vs. 0), primary tumor site (left colorectum vs. right colon), synchronous metastases (yes vs. no), liver metastasis (with vs. without), lung metastasis (with vs. without), previous regorafenib treatment (yes vs. no), baseline neutrophil–lymphocyte ratio (NLR) (≥ 1.5 vs. < 1.5), KRAS status (wide type vs. mutant), BRAF status (wide type vs. mutant), and ERBB2/ERBB3 status (wide type vs. mutant) (Table 3).